Skip to content
ANAVEX
ANAVEXANAVEX
  • HOME
  • ABOUT US
  • OUR TEAM
  • NEWS
  • INVESTORS
    • Events
    • Share Data
    • Analyst Coverage
    • Code of Conduct
    • Investor Material
    • Presentations
  • JOIN US
Search
  • HOME
  • ABOUT US
  • OUR TEAM
  • NEWS
  • INVESTORS
    • Events
    • Share Data
    • Analyst Coverage
    • Code of Conduct
    • Investor Material
    • Presentations
  • JOIN US
View allAlzheimer's DiseaseAnavex2-73EventsNews ReleasesPIPELINEPressUncategorized

A variant of the sigma receptor type 1 gene is a protective factor for Alzheimer’s disease.

Selective M1 muscarinic agonists: failure of therapeutic strategy against Alzheimer’s disease or inappropriate tactics?

Oxidative Damage Is the Earliest Event in Alzheimer Disease

Animal models of Alzheimer’s disease and evaluation of anti-dementia drugs.

Loss of sigma binding sites in the CA1 area of the anterior hippocampus in Alzheimer’s disease correlates with CA1 pyramidal cell loss.

123
ANAVEX

ANAVEX® is a trademark of Anavex®Life Sciences Corp. - 2019 All Rights Reserved

Go to Top